U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial
Authors:
Open Access
- 21 May 2025
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101773
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the USJAMA Network Open, 2024
- Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination SurveyCirculation: Cardiovascular Quality and Outcomes, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease EventsCardiovascular Drugs and Therapy, 2023
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016